Their study demonstrates that it was feasible to simultaneously target GPRC5D and BCMA, and provides insight into optimal dual targeting designs; thus, broadening the arsenal and potential efficacy of cellular therapies for MM. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.